Home›Companies›Biotech & Pharma›resistanceBio

resistanceBio, Inc.

Updated Oct 27, 2026·Latest SEC filing Jan 31, 2024·Suggest an edit

About resistanceBio

resistanceBio is a private company based in Menlo Park, California, incorporated in 2021 in Delaware. It has reported $12,776,288 raised in one offering on Form D since January 2024. Its chief executive is Kyle Lapham.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Jan 29, 2024Jan 31, 2024$12,776,288fully sold44$290KEquity, DebtRule 506(b)Form D ↗

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on resistanceBio's Form D filed Jan 31, 2024.

NG
Nicholas Goldner
Executive officer and director
KL
Kyle Lapham
Chief Executive Officer and director
CB
Christopher Bulow
Executive officer and director

Sources

  1. SECresistanceBio, Inc. filing history